ZIOPHARM Oncology, Inc. (ZIOP)’s Bearish Wedge Down Chart Pattern Points to Higher Stock Risks

March 21, 2018 - By Nellie Frank

The stock of ZIOPHARM Oncology, Inc. (ZIOP) formed a down wedge with $4.13 target or 3.00 % below today’s $4.26 share price. The 6 months wedge indicates high risk for the $600.57M company. If the $4.13 price target is reached, the company will be worth $18.02 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock increased 1.67% or $0.07 during the last trading session, reaching $4.26. About 216,126 shares traded. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 1.75% since March 21, 2017 and is uptrending. It has underperformed by 14.95% the S&P500.

Analysts await ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings on May, 7. They expect $-0.13 EPS, up 13.33 % or $0.02 from last year’s $-0.15 per share. After $-0.13 actual EPS reported by ZIOPHARM Oncology, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology has $9.5 highest and $6 lowest target. $8.25’s average target is 93.66% above currents $4.26 stock price. Ziopharm Oncology had 9 analyst reports since December 4, 2015 according to SRatingsIntel. The firm earned “Underperform” rating on Friday, December 4 by Wells Fargo. The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has “Buy” rating given on Thursday, December 14 by H.C. Wainwright. On Monday, January 25 the stock rating was maintained by Mizuho with “Neutral”. On Thursday, June 2 the stock rating was initiated by Raymond James with “Market Perform”. The firm earned “Buy” rating on Monday, March 5 by H.C. Wainwright. The stock has “Market Perform” rating by Wells Fargo on Wednesday, August 10. The firm has “Neutral” rating by Mizuho given on Wednesday, May 11.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.